The transdermal Skin Patches market was valued at USD 7244.34 million in 2020 and is anticipated to grow at USD 9572.35 million by 2027 recording a CAGR of 4.79% during the forecast period 2021-2027. Transdermal skin patches are the adhesive patches which contain medicaments, placed on the skin and delivers the specific dosage of medication into the blood stream through the skin. Global transdermal skin patches market is primarily driven by the advantages of transdermal skin patches over the oral administration of the medicaments such as ease of administration, enhanced bioavailability, onset of action and prolonged activity of the drug. In addition, adaptation of the transdermal skin patches for the pain relief and new product launches and R&D expected to boost the transdermal skin patches market over the forecast period. Moreover, transdermal skin patches help in effective administration of the drugs which have the narrow therapeutic range. In addition, elimination of the first pass metabolism effected and ease of use effect the prescription of the transdermal skin patches for the drugs having narrow therapeutic window. However, skin permeability of the range of drugs limits the growth of market. Only handful of drugs are suitable for the transdermal drug delivery. Furthermore, disadvantages such as chances of developing contact dermatitis may hamper the market growth over the forecast period. In Febrauary 2015, China National Bluestar (Group) Co, Ltd. has launched Silbone soft silicone adhesive for skin application including transdermal patches.